Francisco trust disposes of $124,957 in Dyadic International stock By Investing.com

Francisco Trust, a 10% owner and director of Dyadic International Inc. (), disposed of shares worth approximately $124,957 in a series of transactions from July 22 to July 24, 2026.

The transactions involved the sale of 38,016 shares on July 22, 2026, 54,760 shares on July 23, 2026, and an additional 2,616 shares on July 24, 2026. The shares were sold at prices ranging from $1.2131 to $1.3279 per share. The sales come after the stock delivered a 32% return over the past six months and a 27% gain year-to-date, according to InvestingPro data. An InvestingPro tip notes the company has shown strong returns over the last three months, though InvestingPro’s Fair Value analysis suggests the stock is slightly overvalued at current levels.

Following these sales, the Francisco Trust directly holds 3,280,272 shares of Dyadic International Inc. common stock. The filing was signed by Thomas Emalfarb, Trustee of Francisco Trust. Investors seeking deeper insights can access a comprehensive Pro Research Report on DYAI, one of 1,400+ US equities covered with expert analysis and actionable intelligence on InvestingPro.

In other recent news, Dyadic International Inc. reported a notable revenue increase of 182% year-over-year for the first quarter of 2026, reaching $1.1 million. Despite this surge in revenue, the company’s earnings per share (EPS) remained at a loss of $0.05, aligning with analysts’ expectations. In addition to financial updates, Dyadic announced the expansion of its bio-industrial pipeline with a new proprietary enzyme program aimed at cellulose processing. This development follows the successful commercialization of its first proprietary bio-industrial enzyme product, EN3ZYME. Furthermore, the company secured a patent from the Japan Patent Office for its Thermothelomyces heterothallica recombinant protein expression technology, enhancing its C1 and Dapibus production platforms. Shareholders recently approved the election of Seth J. Herbst, M.D., as a Class I director at the 2026 Annual Meeting. These developments reflect Dyadic’s ongoing efforts to innovate and expand its technological capabilities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.